Pieris Pharmaceuticals, Inc. (PIRS) News

Pieris Pharmaceuticals, Inc. (PIRS): $1.98

-0.02 (-1.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PIRS to Watchlist
Sign Up

Industry: Biotech


Ranked

of 397

in industry

Filter PIRS News Items

PIRS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PIRS News Highlights

  • PIRS's 30 day story count now stands at 4.
  • Over the past 27 days, the trend for PIRS's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about PIRS are ARIZ, DRUG and HTGM.

Latest PIRS News From Around the Web

Below are the latest news stories about Pieris Pharmaceuticals Inc that investors may wish to consider to help them evaluate PIRS as an investment opportunity.

Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022

BOSTON,MA / ACCESSWIRE /February 23,2022/Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a full-year 2021 investor call on Tuesday, March 1, 2022 at 8:00 AM EST to discuss financial results and provide a corporate update.

Yahoo | February 23, 2022

Companies Like Pieris Pharmaceuticals (NASDAQ:PIRS) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | February 4, 2022

HTG Appoints Biopharmaceutical Industry Veteran Christopher Kiritsy to its Board of Directors

Brings Significant Operational Experience in Building Therapeutic Drug Development BusinessesTUCSON, Ariz., Jan. 28, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced it has appointed biopharmaceutical industry veteran Christopher Kiritsy to its Board of Directors. Currently the Managing Member of Precision Kapital, LLC, a private investment a

Yahoo | January 28, 2022

3 Biotechs That Will Soar Regardless of COVID-19

In the healthcare markets, much time and energy have been focused on COVID-19. But there are some amazing opportunities outside the COVID space.

Yahoo | January 27, 2022

2 Risky Growth Stocks That Could Make You Filthy Rich

Growth stocks, on balance, have fallen out of favor in recent months. Political gridlock in Washington, D.C., historically high inflation rates, and concerns about an interest rate increase have dampened investors' appetite for risk. Which unloved biotech stocks should risk-tolerant investors have on their radar right now?

Yahoo | January 16, 2022

Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa

BOSTON,MA / ACCESSWIRE / January 14,2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that the first patient has been dosed in the phase 2 study of cinrebafusp alfa (PRS-343), a 4-1BB/HER2 Anticalin-based bispecific for the treatment of HER2-expressing gastric cancer.

Yahoo | January 14, 2022

Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402

BOSTON,MA / ACCESSWIRE / January 3, 2022 /Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced the successful completion of the sponsor safety review of part 1a of the multi-center, placebo-controlled phase 2a study of dry powder inhaler-formulated PRS-060/AZD1402.

Yahoo | January 3, 2022

Do Options Traders Know Something About Pieris Pharmaceuticals (PIRS) Stock We Don't?

Investors need to pay close attention to for Pieris Pharmaceuticals (PIRS) stock based on the movements in the options market lately.

Yahoo | December 15, 2021

How Many Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Shares Do Institutions Own?

A look at the shareholders of Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ) can tell us which group is most powerful...

Yahoo | December 6, 2021

Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences

BOSTON,MA / ACCESSWIRE /November 11,2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that members of the management team will participate in the following upcoming investor conferences:Jefferies London Healthcare ConferenceThursday, November 18, 2021 at 8:00 AM GMT.

Yahoo | November 11, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4141 seconds.